Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999-2006)

Journal of the American Veterinary Medical Association

Volumn 233, Issue 3, 2008, Pages 446-451

  Bannink, Erin O ^a,c   Sauerbrey, Michele L ^a,c   Mullins, Marie N ^a,d   Hauptman, Joe G ^b   Obradovich, Joyce E ^a  

^a Animal Cancer & Imaging Center Michigan   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Oakland Veterinary Referral Services   (United States)

^d Veterinary Cancer Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DACTINOMYCIN; PREDNISONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DISEASE FREE SURVIVAL; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; LYMPHOMA; MALE; MORTALITY; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LYMPHOMA; MALE; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 48749127046     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.233.3.446     Document Type: Article

References (33)

1. Vail DM, MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, MacEwan EG, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;569-570.
2. Vail DM, Young KM. Hematopoietic tumors: canine lymphoma and lymphoid leukemia. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's small animal clinical oncology. 4th ed. St Louis: WB Saunders Co, 2007;716.
3. Vail DM. Recent advances in chemotherapy for lymphoma of dogs and cats. Campend Contin Educ Pract Vet 1993;15:1031-1036.
4. Kitchell BE, Dhaliwal RS. CVT update: anticancer drugs and protocols using traditional drugs. In: Bonagura JD, eds. Kirk's current veterinary therapy XIII. Philadelphia: WB Saunders Co, 2000;465-473.
5. Hammer AS, Couto CG, Ayl RD, et al. Treatment of tumor-bearing dogs with actinomycin D. J Vet Intern Med 1994;8:236-239.
6. Lucroy MD, Phillips BS, Kraegel SA, et al. Evaluation of singleagent mitoxantrone as chemotherapy for relapsing canine lymphoma. J Vet Intern Med 1998;12:325-329.
7. Moore AS, Ogilvie GK, Vail DM. Actinomycin D for reinduction of remission in dogs with resistant lymphoma. J Vet Intern Med 1994;8:343-344.
8. Moore AS, Ogilvie GK, Ruslander D, et al. Evaluation of mitoxantrone for the treatment of lymphoma in dogs. J Am Vet Med Assoc 1994;204:1903-1905.
9. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-398.
10. VanVechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990;4:187-191.
11. Dervisis NG, Dominguez PA, Sarbu L, et al. Efficacy of temazolamide or decarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. J Am Vet Med Assoc 2007;231:563-569.
12. Saba CF, Thamm DH, Vail DM. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med 2007;21:127-132.
13. Rassnick KM, Mauldin GE, Al-Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). J Vet Intern Med 2002;16:576-580.
14. Calvert CA, Leifer CE. Doxorubicin for treatment of canine lymphosarcoma after development of resistance to combination chemotherapy. J Am Vet Med Assoc 1981;179:1011-1012.
15. Alvarez FJ, Kisseberth WC, Gallant SL, et al. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma. J Vet Intern Med 2006;20:1178-1183.
16. LeBlanc AK, Mauldin GE, Milner RJ, et al. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Vet Comp Oncol 2006;4:21-32.
17. Hohenhaus AE, Matus RE. Etoposide (VP-16). Retrospective analysis of treatment in 13 dogs with lymphoma. J Vet Intern Med 1990;4:239-241.
18. Chun R, Garrett LD, Vail DM. Cancer chemotherapy. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's small animal clinical oncology. 4th ed. St Louis: WB Saunders Co, 2007;177-178.
19. Chabner BA. Clinical strategies for cancer treatment: the role of drugs. In: Chabner BA, Collins LB, eds. Cancer chemotherapy principles and practice. Philadelphia: JB Lippincott, 1989;1-15.
20. Siedlecki CT, Kass PH, Jakubiak MJ, et al. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma. Can Vet J 2006;47:52-59.
21. deLorimier LP, Kitchell BE. Dactinomycin. Compend Contin Educ Pract Vet 2004;26(4):270-273.
22. MacDonald VS, Thamm DH, Kurzman ID, et al. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
23. Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats vl.O. Vet Comp Oncol 2004;2:195-213.
24. Owen LN. TNM classification of tumors in domestic animals. Geneva: World Health Organization, 1980;46-47.
25. Demetri GD, Anderson KC. Disorders of blood cell production in clinical oncology. In: Abeloff MD, Armitage JO, Niederhuber JE, eds. Clinical oncology. 3rd ed. Philadelphia: Elsevier Inc, 2004;865.
26. Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequestial analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996; 10:354-359.
27. Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995;13:475-479.
28. Cole SPC, Tannock IF. Drug resistance. In: Tannock IF, Hill RP, Bristow RG, eds. The basic science of oncology. 4th ed. New York: McGraw-Hill Book Co, 2005;377-397.
29. Takimoto CH. Pharmacology of cancer chemotherapy: topoisomerase interactive agents. In: DeVita VT, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;388.
30. Stewart J, Gorman NT. Multi-drug resistance genes in the management of neoplastic disease. J Vet Intern Med 1991;5:239-247.
31. Choi K, Chen CJ, Kriegler M, et al. An altered pattern of crossresistance in multidrug-resistant human cells results from spontaneous mutations in the mdrl (P-glycoprotein) gene. Cell 1988;53:519-529.
32. Price G, Page R, Fischer B, et al. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991;5: 259-262.
33. Khanna C, Lund EM, Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 1998;213:985-990.